Inventor · disambiguated record
James A. Radosevich
Also filed as: RADOSEVICH JAMES · RADOSEVICH JAMES A
11 granted patents·11 pending applications·69 citations·filing 1986–2020
89Inventor score
Files withIMMVARX INC4IMMTECH INTERNAT INC3RADOSEVICH JAMES3IMMTECH INT INC2LABYRX IMMUNOLOGIC THERAPEUTICS USA LTD2
Top patents by PatentIndex Score
22 records- 0183US7635759B2Gene encoding labyrinthin, a marker for cancerIMMVARX INC·Filed 2008·Granted Dec 22, 2009·4 cites·3 claims
- 0277US6727080B1Gene encoding labyrinthin, a marker for cancerIMMVARX INC·Filed 2000·Granted Apr 27, 2004·7 cites·7 claims
- 0374US6166176ACancer marker protein and peptides thereofIMMVARX INC·Filed 1998·Granted Dec 26, 2000·22 cites·7 claims
- 0473US7329743B2Gene encoding labyrinthin, a marker for cancerIMMVARX INC·Filed 2004·Granted Feb 12, 2008·4 cites·4 claims
- 0571US8163883B2Gene encoding labyrinthin, a marker for cancerRADOSEVICH JAMES·Filed 2009·Granted Apr 24, 2012·1 cites·14 claims
- 0670US6455046B1Use of mCRP to enhance immune responsesIMMTECH INT INC·Filed 2000·Granted Sep 24, 2002·1 cites·3 claims
- 0758US2003021798A1Use of mCRP to enhance immune responsesIMMTECH INTERNAT INC·Filed 2002·Application pending·0 cites
- 0858US2017175084A1Tumor stem cellsUNIV ILLINOIS·Filed 2017·Application pending·0 cites
- 0957US4816402AMurine hybridoma and diagnostic antibody produced therebyUNIV NORTHWESTERN·Filed 1986·Granted Mar 28, 1989·19 cites·2 claims
- 1057US2013252236A1Tumor stem cellsUNIV ILLINOIS·Filed 2012·Application pending·0 cites
- 1156US6280743B1Use of mCRP to enhance immune responsesIMMTECH INT INC·Filed 2000·Granted Aug 28, 2001·0 cites·7 claims
- 1255US6331403B1Use of mCRP to slow cell growth and to promote maturation of cellsFiled 1999·Granted Dec 18, 2001·9 cites·8 claims
- 1353US2011293525A1Tumor stem cellsRADOSEVICH JAMES A·Filed 2011·Application pending·0 cites
- 1449US2002037535A1Use of mCRP to slow cell growth and to promote maturation of cellsIMMTECH INTERNAT INC·Filed 2001·Application pending·0 cites
- 1549US2022409709A1Labyrinthin-based peptides for cancer immunotherapies and uses thereofLABYRX IMMUNOLOGIC THERAPEUTICS USA LTD·Filed 2019·Application pending·0 cites
- 1648US2022089719A1Constructs targeting labyrinthin or a portion thereof and uses thereofLABYRX IMMUNOLOGIC THERAPEUTICS USA LTD·Filed 2020·Application pending·0 cites
- 1748US2010233711A1Gene encoding labyrinthin, a marker for cancerRADOSEVICH JAMES·Filed 2010·Application pending·0 cites
- 1848US2011110963A1Gene encoding labyrinthin, a marker for cancerRADOSEVICH JAMES·Filed 2010·Application pending·0 cites
- 1939US2002061843A1Use of mCRP for delivery of materials into cellsFiled 2001·Application pending·0 cites
- 2031US2011293753A1Tocotrienol CompositionsBELLAFIORE LOUIS·Filed 2010·Application pending·0 cites
- 2129US6190670B1Use of mCRP to enhance immune responsesIMMTECH INTERNAT INC·Filed 1999·Granted Feb 20, 2001·0 cites·2 claims
- 2221US4756346AProcess and apparatus for the preparation of multiple gradientsUS HEALTH·Filed 1986·Granted Jul 12, 1988·2 cites·7 claims
Join the waitlist — get patent alerts
Get an alert when James A. Radosevich files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →